الفهرس 
HCV InfectionOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Background: Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) which mainly attacks the liver cells. The acute stage of the disease passes mostly without manifestations, but the chronic stage can cause hepatic fibrosis and cirrhosis, that has mostly occurred after several years. Some cirrhotic patients may develop liver failure, hepatocellular carcinoma (HCC) or fatal bleeding from esophageal or gastric varices. HCV_4 is prevalent among Middle East and Africa causing more than 80% of HCV infections and has recently spread to several European countries. In Egypt, HCV-4 responsible for almost 90% of the infections. Aim: The aim of this study is to evaluate the glycemic control in diabetic patients with chronic HCV infection after eradication of HCV by sofosbuvir plus daclatasvir with or without ribavirin regimen through HbA1c measurement before the start of treatment, at the end of treatment, and 3 months after the end of treatment. Methodology: This study has been conducted at Viral Hepatitis unit - Ahmed Maher Teaching Hospital and Ain Shams University Hospital - the National Committee to Combat Viral Hepatitis (NCCVH) in Egypt during period from October 2016 to September 2017. One hundred (100) Egyptian diabetic patients with chronic HCV infection eligible for treatment were recruited in this study and were divided as follows: group I: 50 patients recieving oral hypoglycemic drugs. group II: 50 patients recieving insulin therapy. Both groups received sofosbuvir (400mg) plus daclatasvir (60mg) daily for 12 weeks with or without ribavirin. Results: No hypoglycemic attacks were reported throughout our study. In our study mean values of baseline alanine transaminase (ALT) and aspartate transaminase (AST) in both groups was significantly decreased at end of treatment. In both groups, there is a significant decline of HbA1C value at the end of treatment and 3 months after end of treatment. Conclusion: The glycemic control is significantly improved in diabetic patients after eradication of HCV by new DAAs regimens